Journal of Pediatric Nursing
Volume 24, Issue 3 , Pages 179-188 , June 2009

Nurses' Genetic/Genomics Competencies when Medication Therapy is Guided by Pharmacogenetic Testing: Children with Mental Health Disorders as an Exemplar

References 

  1. Bevan JL, Lynch JA, Dubriwny TN, Harris TM, Achter PJ, Reeder AL, et al. Informed lay preferences for delivery of racially varied pharmacogenomics. Genetics in Medicine. 2003;5:393–399
  2. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229–243
  3. Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials. Journal of the American Medical Association. 2007;297:1683–1696
  4. Buchanan A, Califano A, Kahn J, McPherson E, Robertson J, Brody B. Pharmacogenetics: Ethical issues and policy options. Kennedy Institute of Ethics Journal. 2002;12:1–15
  5. Chou WH, Yan FX, de Leon J, Barnhill J, Rogers T, Cronin M, et al. Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. Journal of Clinical Psychopharmacology. 2000;20:246–251
  6. Consensus Panel on Genetic/Genomic Nursing Competencies . Essential nursing competencies and curricula guidelines for genetics and genomics. Silver Spring, MD: American Nurses Association; 2006;
  7. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annual Review of Medicine. 2006;57:119–137
  8. Emslie G, Kratochvil C, Vitiello B, Silva S, Mayes T, McNulty S, et al. Treatment for adolescents with depression study (TADS): Safety results. Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45:1440–1455
  9. Evans WE, McLeod HL. Pharmacogenomics—Drug disposition, drug targets, and side effects. New England Journal of Medicine. 2003;348:538–549
  10. Flockhart DA. Drug interaction table (cytochrome P450 system). http://medicine.iupui.edu/flockhartRetrieved November 15, 2007, from
  11. Genetics and Pubic Policy Center . U.S. public opinion on uses of genetic information and genetic discrimination. Washington D.C.: Genetics and Pubic Policy Center; 2007;
  12. Henrikson NB, Burke W, Veenstra DL. Ancillary risk information and pharmacogenetic tests: Social and policy implications. Pharmacogenomics J. 2007;advance online publication, 8 May 2007
  13. Jenkins J, Calzone KA. Establishing the essential nursing competencies for genetics and genomics. Journal of Nursing Scholarship. 2007;39:10–16
  14. Kalow W. Pharmacogenetics and pharmacogenomics: Origin, status, and the hope for personalized medicine. Pharmacogenomics Journal. 2006;6:162–165
  15. Kinney AY. Genetic testing for colorectal carcinoma susceptibility: Focus group responses of individuals with colorectal carcinoma and first-degree relatives. Cancer. 2001;91:57–65
  16. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: A first step towards subpopulation-specific dosages. Acta Psychiatrica Scandinavica. 2001;104:173–192
  17. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, et al. Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry. 2004;9:442–473
  18. Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochimica et Biophysica Acta. 2007;1770:489–494
  19. Kootstra-Ros JE, Van Weelden MJ, Hinrichs JW, De Smet PA, van der Weide J. Therapeutic drug monitoring of antidepressants and cytochrome p450 genotyping in general practice. Journal of Clinical Pharmacology. 2006;46:1320–1327
  20. Kropp S, Lichtinghagen R, Winterstein K, Schlimme J, Schneider U. Cytochrome P-450 2D6 and 2C19 polymorphisms and length of hospitalization in psychiatry. Clinical Laboratory. 2006;52:237–240
  21. Leeder JS. Pharmacogenetics and pharmacogenomics. Pediatric Clinics of North America. 2001;48:765–781
  22. MacDonald DJ. Genetic predisposition testing for cancer: Effects on families' lives. Holistic Nursing Practice. 1998;12:9–19
  23. Maradiegue A, Edwards QT. An overview of ethnicity and assessment of family history in primary care settings. Journal of the American Academy of Nurse Practitioners. 2006;18:447–456
  24. March J, Silva S, Vitiello B. The treatment for adolescents with depression study (TADS): Methods and message at 12 weeks. Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45:1393–1403
  25. Mayo Clinic offers new genetic test to screen for side effects of antidepressant treatment. Pharmacogenomics. 2006;7:811
  26. McLeod HL. Pharmacogenetic analysis of clinically relevant genetic polymorphisms. Clinical Infectious Diseases. 2005;41(Suppl 7):S449–S452
  27. Michelson S, Joho K. Drug discovery, drug development and the emerging world of pharmacogenomics: Prospecting for information in a data-rich landscape. Current Opinion in Molecular Therapeutics. 2000;2:651–654
  28. Mulder H, Wilmink FW, Beumer TL, Tamminga WJ, Jedema JN, Egberts AC. The association between cytochrome P450 2D6 genotype and prescription patterns of antipsychotic and antidepressant drugs in hospitalized psychiatric patients: A retrospective follow-up study. Journal of Clinical Psychopharmacology. 2005;25:188–191
  29. Murphy DL, Lerner A, Rudnick G, Lesch KP. Serotonin transporter: Gene, genetic disorders, and pharmacogenetics. Molecular Interventions. 2004;4:109–123
  30. Murray M. Role of CYP pharmacogenetics and drug–drug interactions in the efficacy and safety of atypical and other antipsychotic agents. Journal of Pharmacy and Pharmacology. 2006;58:871–885
  31. Perlis RH. Pharmacogenetic studies of antidepressant response: How far from the clinic?. Psychiatric Clinics of North America. 2007;30:125–138
  32. In:  Porter RS,  Kaplan JL editor. Merck Manuals Online Medical Library for Healthcare Professionals. Whitehouse Station, NJ: Merck Research Laboratories; 2006–2007;http://www.merck.com/mmpe/index.html(accessed July 12, 2007)
  33. Roses AD. Pharmacogenetics and the practice of medicine. Nature. 2000;405:857–865
  34. Roth MT, Painter RB. Genetic discrimination in health insurance: An overview and analysis of the issues. Nursing Clinics of North America. 2000;35:731–756
  35. Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clinical Pharmacology and Therapeutics. 2008;83:322–327
  36. Ruhe HG, Huyser J, Swinkels JA, Schene AH. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: Systematic review. British Journal of Psychiatry. 2006;189:309–316
  37. Ruhe HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: A systematic review. Journal of Clinical Psychiatry. 2006;67:1836–1855
  38. Scharf MA, Williams TP. Psychopharmacology in adolescent medicine. Adolescent Medicine Clinics. 2006;17:165–181
  39. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clinical Pharmacology and Therapeutics. 2006;79:103–113
  40. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenetics and Genomics. 2007;17:93–101
  41. Springhouse Corporation . Nursing drug handbook 2008. (28th ed.). Springhouse, PA: Lippincott Williams & Wilkins; 2007;
  42. Swen JJ, Huizinga TW, Gelderblom H, de Vries EG, Assendelft WJ, Kirchheiner J, et al. Translating pharmacogenomics: Challenges on the road to the clinic. PLoS Medicine. 2007;4:e209
  43. Tamminga WJ, Wemer J, Oosterhuis B, de Boer A, Vranckx S, Drenth BF, et al. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: A retrospective study. European Journal of Clinical Pharmacology. 2003;59:57–64
  44. Van Riper M. Genetic testing and the family. Journal of Midwifery and Women's Health. 2005;50:227–233
  45. Vaszar LT, Cho MK, Raffin TA. Privacy issues in personalized medicine. Pharmacogenomics. 2003;4:107–112
  46. Weinshilboum R. Inheritance and drug response. New England Journal of Medicine. 2003;348:529–537
  47. Weinshilboum R, Wang L. Pharmacogenomics: Bench to bedside. Nature Reviews. Drug Discovery. 2004;3:739–748
  48. Williams JK, Schutte DL, Evers CA, Forcucci C. Adults seeking presymptomatic gene testing for Huntington disease. Image–The Journal of Nursing Scholarship. 1999;31:109–114

PII: S0882-5963(08)00150-4

doi: 10.1016/j.pedn.2008.02.033

Journal of Pediatric Nursing
Volume 24, Issue 3 , Pages 179-188 , June 2009

Article Tools